BioNTech SE and its partner Duality Biologics announced a successful interim analysis from their Phase III trial involving trastuzumab pamirtecan, an HER2-targeting antibody-drug conjugate (ADC), in patients with HER2-positive unresectable or metastatic breast cancer. The trial achieved its primary endpoint of progression-free survival, marking BioNTech’s first Phase III oncology success and positioning Duality Biologics for a potential biological license application in China. The data contrast favorably with Roche's Kadcyla, suggesting significant competitive potential in this indication. The results elevate expectations for the ongoing global late-phase study.